CytoMed Therapeutics Limited Comprehensive Income Attributable To Noncontrolling Interests
CytoMed Therapeutics Limited (GDTC) reported Comprehensive Income Attributable To Noncontrolling Interests of -SGD 15.88 thousand for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-31.
Financial Statements › Income Statement › Unrealized Gains
ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests · last filed 2026-03-31
SGD
| Period end | Comprehensive Income Attributable To Noncontrolling Interests 12 month |
|---|---|
| 2025-12-31 | -15.88K SGD 20-F · filed 2026-03-31 |
| 2024-12-31 | -5.16K SGD 20-F · filed 2026-03-31 |
| 2023-12-31 | -274.00 SGD 20-F · filed 2026-03-31 |
| 2022-12-31 | -243.00 SGD 20-F · filed 2025-04-28 |
| 2021-12-31 | -253.00 SGD 20-F · filed 2024-04-22 |
| 2020-12-31 | -186.00 SGD 20-F · filed 2023-05-01 |
USD
| Period end | Comprehensive Income Attributable To Noncontrolling Interests 12 month |
|---|---|
| 2025-12-31 | -$12.35K 20-F · filed 2026-03-31 |
| 2024-12-31 | -$3.78K 20-F · filed 2025-04-28 |
| 2023-12-31 | -$208.00 20-F · filed 2024-04-22 |
| 2022-12-31 | -$181.00 20-F · filed 2023-05-01 |